LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

Search

IQVIA Holdings Inc

Closed

SectorHealthcare

141.79 -6.01

Overview

Share price change

24h

Current

Min

141.67

Max

150.94

Key metrics

By Trading Economics

Income

-188M

249M

Sales

-129M

3.8B

P/E

Sector Avg

21.3

56.602

EPS

2.7

Profit margin

6.503

Employees

89,000

EBITDA

-281M

740M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+25.03% upside

Dividends

By Dow Jones

Next Earnings

21 Jul 2025

Market Stats

By TradingEconomics

Market Cap

-8.6B

27B

Previous open

147.8

Previous close

141.79

News Sentiment

By Acuity

75%

25%

358 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

IQVIA Holdings Inc Chart

Past performance is not a reliable indicator of future results.

Related News

14 May 2025, 23:40 UTC

Hot Stocks

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 May 2025, 23:33 UTC

Major Market Movers

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 May 2025, 23:25 UTC

Major Market Movers

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 May 2025, 23:25 UTC

Earnings

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 May 2025, 22:58 UTC

Earnings

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 May 2025, 21:35 UTC

Earnings

Cisco Systems Names Patterson as CFO, Patel as President

14 May 2025, 23:59 UTC

Market Talk

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 May 2025, 23:49 UTC

Market Talk

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 May 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

14 May 2025, 23:48 UTC

Market Talk

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 May 2025, 23:47 UTC

Market Talk

Gold Gains on Possible Technical Recovery -- Market Talk

14 May 2025, 23:34 UTC

Acquisitions, Mergers, Takeovers

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 May 2025, 23:10 UTC

Earnings

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 May 2025, 23:07 UTC

Earnings

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 May 2025, 23:00 UTC

Top News

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 May 2025, 22:43 UTC

Earnings

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 May 2025, 22:34 UTC

Earnings

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 May 2025, 22:33 UTC

Earnings

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 May 2025, 22:30 UTC

Earnings

Xero Did Not Declare a Dividend>XRO.AU

14 May 2025, 22:30 UTC

Earnings

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 May 2025, 22:30 UTC

Earnings

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 May 2025, 22:30 UTC

Earnings

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 May 2025, 22:28 UTC

Earnings

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 May 2025, 22:28 UTC

Earnings

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 May 2025, 22:27 UTC

Earnings

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 May 2025, 22:27 UTC

Earnings

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 May 2025, 22:23 UTC

Top News

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 May 2025, 22:15 UTC

Earnings

Correction to Cisco Earnings Article -- WSJ

14 May 2025, 21:48 UTC

Earnings

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 May 2025, 21:37 UTC

Earnings

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Peer Comparison

Price change

IQVIA Holdings Inc Forecast

Price Target

By TipRanks

25.03% upside

12 Months Forecast

Average 188.4 USD  25.03%

High 232 USD

Low 160 USD

Based on 16 Wall Street analysts offering 12 month price targets forIQVIA Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

16 ratings

11

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

150.68 / 153.45Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Neutral Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

358 / 382 Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.